| Aspen Acquire Antibiotic Range Friday, 20 January 2006 - Aspen Australia |
| Effective today (16 January), Aspen Pharma have taken over the sales, marketing and distribution of Austrapen, Moxacin and Flopen from CSL. This portfolio is projected to add $2mio to $3mio annually to our sales, and puts us in the position of being one of the leading suppliers of injectable antibiotics in Australia (penicillins, cephalosporins, vancomycin, and “last-line” antibiotic). The CSL products will complement our current range, which already includes Flucil, Fisamox and Ampicyn. |
Related Articles : |